Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safetyexpansion of selected doses, and a Phase 2 (expansion cohorts)
The study consists of two main parts to explore the recommended dosing of BGB-16673: a phase 1 to determine the monotherapy dose, which consists of an escalation of the monotherapy dose and an extension of the monotherapy safety of selected doses, and a phase 2 (extension cohorts).
